On October 23, 2026, a Phase 2 clinical trial listed on ClinicalTrials.gov under identifier NCT06394804 was recorded as recruiting. The trial is titled "A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer." This study is being conducted in the Phase 2 stage of clinical development. Its current status is recruiting, meaning the trial is actively seeking participants as of the listed date. No results or outcome data have been reported for this trial at this time. The event record does not specify efficacy, safety findings, or comparative data beyond the trial's status and phase. Leuprolide is an approved compound, and its regulatory status remains unchanged by this trial update. This brief reflects only the recruitment status and title information provided in the trial record as of the stated date. Readers interested in the broader context of leuprolide, including its approved uses and regulatory history, can consult the compound overview for additional background.
Phase 2 Trial Involving Leuprolide Combination Now Recruiting
See the full leuprolide overview
Source: https://clinicaltrials.gov/study/NCT06394804